---
title: "Effectiveness and Safety of Tocilizumab in Refractory Rheumatoid Arthritis: A Moroccan Study"
id: "medrxiv-12-real-world-effectiveness-and-safety-of-tocilizumab-in-refractory-rheumatoid"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-12-real-world-effectiveness-and-safety-of-tocilizumab-in-refractory-rheumatoid"
content_type: "clinical_feed_article"
specialty: "Rheumatology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.27.26361508v1?rss=1"
published_at: "2026-08-28T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Effectiveness and Safety of Tocilizumab in Refractory Rheumatoid Arthritis: A Moroccan Study
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-12-real-world-effectiveness-and-safety-of-tocilizumab-in-refractory-rheumatoid
- **Specialty:** [Rheumatology](https://medichelpline.com/clinical-feed/rheumatology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.27.26361508v1?rss=1)
- **Published At:** 2026-08-28T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- **Tocilizumab** (TCZ) is a monoclonal antibody targeting the interleukin-6 receptor, utilized in rheumatoid arthritis (RA). - This study evaluated TCZ's real-world effectiveness and safety in **44 Moroccan** RA patients after inadequate responses to previous treatments. - Conducted at Moulay Ismail Hospital, data was collected from **April 2019 to January 2024**. - 75% of participants were women, with a median age of **57** years and a mean RA duration of approximately **13 years**. - Prior to TCZ, patients had experienced on average **2.5** previous DMARDs and **93.2%** had received **biological agents**. - At the **6-month** mark, 67.6% achieved a good EULAR response while 35.3% attained **DAS28-ESR** remission. - Disease activity significantly decreased over the study period, indicated by reduced DAS28-ESR scores. - Adverse events included **22 infections**, with one serious that required hospitalization; liver enzyme changes were also noted. - Significant associations with EULAR response included **rheumatoid-factor positivity** and baseline tender joints. - Limitations include the study's retrospective nature and small sample size, suggesting findings are preliminary.
## Clinical Analysis & Structured Key Points
Real-World Effectiveness and Safety of Tocilizumab in Refractory Rheumatoid Arthritis: A Retrospective Single-Centre Cohort Study of 44 Patients in Morocco | medRxiv Skip to main content Real-World Effectiveness and Safety of Tocilizumab in Refractory Rheumatoid Arthritis: A Retrospective Single-Centre Cohort Study of 44 Patients in Morocco View ORCID Profile Najoua Ghani doi: https://doi.org/10.64898/2026.08.27.26361508 Najoua Ghani Euromed University of Fez Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Najoua Ghani For correspondence: n.ghani{at}ueuromed.org Abstract Info/History Metrics Data/Code Preview PDF Abstract Background. Tocilizumab (TCZ), a monoclonal antibody directed against the interleukin-6 receptor, is used in rheumatoid arthritis (RA) after inadequate response or secondary loss of response to conventional synthetic and biological disease-modifying antirheumatic drugs (DMARDs). Real-world data from North African cohorts remain scarce. We assessed the effectiveness and safety of TCZ in routine care and explored baseline factors associated with 6-month outcomes. Methods. We conducted a retrospective, single-centre cohort study of 44 consecutive patients with RA treated with TCZ between April 2019 and January 2024 in the Department of Rheumatology, Moulay Ismail Hospital, Meknes, Morocco. Demographic, clinical, laboratory, treatment and follow-up data were extracted from medical records using a standardised electronic form. The primary effectiveness outcome was the European Alliance of Associations for Rheumatology (EULAR) response at 6 months; DAS28-ESR remission was defined as DAS28-ESR below 2.6. Safety outcomes comprised infections, neutropenia, liver-enzyme abnormalities and lipid abnormalities. Longitudinal changes were compared with the Wilcoxon signed-rank test, and associations between baseline variables dichotomised at their median and 6-month outcomes were examined with chi-square tests, in SPSS version 29. Results. The cohort comprised 33 women (75.0%), with a median age of 57 years (range 32-82) and a mean RA duration of 12.97+/-9.1 years. Patients had received a mean of 2.5+/-1.8 previous conventional DMARDs, and 41 (93.2%) had received at least one previous biological agent, including two or more tumour necrosis factor (TNF) inhibitors in 36 (81.8%). At 6 months, outcome data were available for 34 patients: 23 (67.6%) achieved a good EULAR response, 6 (17.6%) a moderate response and 5 (14.7%) no response; 12 (35.3%) were in DAS28-ESR remission. Mean DAS28-ESR fell from 5.10+/-1.18 at baseline to 2.74+/-1.38 at 6 months and 2.45+/-1.33 at 12 months, and the mean prednisone-equivalent dose fell from 8.3+/-7.1 to 5 mg/day. Twenty-two infectious episodes were recorded, including one serious infection (purulent pleurisy) requiring hospitalisation; 5 patients (11.4%) had a temporary interruption and 1 (2.3%) a permanent discontinuation for hepatic cytolysis. A neutrophil count below 1,500/mm3 occurred in 13 patients (29.5%), with no count below 1,000/mm3, while mean neutrophils declined from 6.3+/-3.0 to 2.6+/-1.2 G/L at 12 months. Mean LDL cholesterol rose from 1.18 to 1.49 g/L and HDL cholesterol from 0.58 to 0.82 g/L. Rheumatoid-factor positivity was the only baseline variable associated with the EULAR response category (p=0.007); a baseline tender joint count above six was associated with a lower remission rate (23.5%, p=0.007), as was, borderline, a pain visual analogue scale above 65 mm (31.2%, p=0.05). Conclusions. In this heavily pretreated real-world RA cohort, TCZ was associated with a substantial and sustained reduction in disease activity and a manageable safety profile consistent with its known signals. A high baseline articular and pain burden was associated with a lower probability of remission. The small sample, incomplete 6-month follow-up, retrospective design and absence of adjusted effect estimates limit interpretation, and the reported associations should be regarded as hypothesis-generating. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Research Ethics Committee of the Faculty of Medicine, Euromed University of Fez, Morocco. The Committee granted an exemption from full ethics review and waived the requirement for individual written informed consent, the study being a retrospective, non-interventional analysis of irreversibly anonymised records generated during routine clinical care. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability The anonymised dataset generated and analysed during the present study is not publicly available owing to institutional restrictions on the sharing of patient-level clinical data. It is available from the corresponding author on reasonable request and subject to institutional approval. Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Back to top Previous Next Posted August 28, 2026. Download PDF Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Real-World Effectiveness and Safety of Tocilizumab in Refractory Rheumatoid Arthritis: A Retrospective Single-Centre Cohort Study of 44 Patients in Morocco Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Real-World Effectiveness and Safety of Tocilizumab in Refractory Rheumatoid Arthritis: A Retrospective Single-Centre Cohort Study of 44 Patients in Morocco Najoua Ghani medRxiv 2026.08.27.26361508; doi: https://doi.org/10.64898/2026.08.27.26361508 Share This Article: Copy Citation Tools Real-World Effectiveness and Safety of Tocilizumab in Refractory Rheumatoid Arthritis: A Retrospective Single-Centre Cohort Study of 44 Patients in Morocco Najoua Ghani medRxiv 2026.08.27.26361508; doi: https://doi.org/10.64898/2026.08.27.26361508 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (612) Allergy and Immunology (893) Anesthesia (325) Cardiovascular Medicine (4754) Dentistry and Oral Medicine (474) Dermatology (406) Emergency Medicine (640) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1610) Epidemiology (15808) Forensic Medicine (32) Gastroenterology (1194) Genetic and Genomic Medicine (6971) Geriatric Medicine (727) Health Economics (1051) Health Informatics (4961) Health Policy (1422) Health Systems and Quality Improvement (1731) Hematology (578) HIV/AIDS (1330) Infectious Diseases (except HIV/AIDS) (16230) Intensive Care and Critical Care Medicine (1158) Medical Education (661) Medical Ethics (150) Nephrology (718) Neurology (7165) Nursing (362) Nutrition (1072) Obstetrics and Gynecology (1226) Occupational and Environmental Health (999) Oncology (3563) Ophthalmology (1032) Orthopedics (392) Otolaryngology (445) Pain Medicine (464) Palliative Medicine (139) Pathology (702) Pediatrics (1771) Pharmacology and Therapeutics (731) Primary Care Research (758) Psychiatry and Clinical Psychology (5816) Public and Global Health (9666) Radiology and Imaging (2373) Rehabilitation Medicine and Physical Therapy (1428) Respiratory Medicine (1238) Rheumatology (632) Sexual and Reproductive Health (762) Sports Medicine (572) Surgery (763) Toxicology (106) Transplantation (301) Urology (285)
## Related Clinical Research

- [Case report: ADMIO type 1 linked to de novo STAT3 gain-of-function mutation](https://medichelpline.com/clinical-feed/frontiers-in-immunology-16-a-case-report-of-admio-type-1-caused-by-a-de-novo-stat3-gain-of-function.md)
- [Semaglutide and Primary Prevention of MACCE in Obese Adults with T2DM and Rheumatoid Arthritis](https://medichelpline.com/clinical-feed/pubmed-42334436.md) (DOI: 10.1093/ehjcvp/pvag044)
- [Climate change worsens health for people with chronic illness](https://medichelpline.com/clinical-feed/stat-news-1-opinion-climate-change-is-making-people-with-chronic-illness-even-sicker.md)
- [ABO Blood Groups and Disease Risk: Links to Cardiovascular Disease, Cancer, Diabetes, Malaria, COV](https://medichelpline.com/clinical-feed/pubmed-42574721.md) (DOI: 10.1080/07853890.2026.2710922)
- [SGLT2 Inhibitors and Rheumatoid Arthritis Risk in Type 2 Diabetes: Summary of Reported Emulated Ta](https://medichelpline.com/clinical-feed/frontiers-in-immunology-19-the-association-between-sglt2-inhibitors-and-rheumatoid-arthritis-risk-in-type.md)

## Navigation
- [← Back to Rheumatology Feed](https://medichelpline.com/clinical-feed/rheumatology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.